High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical

Anne-Sophie Chretien1,2, Raynier Devillier3,2,4, Samuel Granjeaud5

  • 1Team Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University UM105, 13009 Marseille, France; anne-sophie.chretien@inserm.fr.

Related Concept Videos